Trial Review

The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT01224366




Registration number
NCT01224366
Ethics application status
Date submitted
18/10/2010
Date registered
20/10/2010
Date last updated
23/02/2017

Titles & IDs
Public title
Efficacy and Safety of Vildagliptin as add-on Therapy to Insulin in Patients With Type 2 Diabetes Mellitus
Scientific title
A 24-week, Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Assess the Efficacy and Safety of Vildagliptin 50mg Bid as an add-on Therapy to Insulin, With or Without Metformin, in Patients With Type 2 Diabetes Mellitus.
Secondary ID [1] 0 0
CLAF237A23135
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Type 2 Diabetes Mellitus 0 0
Condition category
Condition code
Metabolic and Endocrine 0 0 0 0
Diabetes

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Experimental: Vildagliptin -

Placebo comparator: Placebo -

Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
HbA1c reduction
Timepoint [1] 0 0
24 weeks
Secondary outcome [1] 0 0
HbA1c reduction in subpopulation treated with insulin and with metformin
Timepoint [1] 0 0
24 weeks
Secondary outcome [2] 0 0
HbA1c reduction in subpopulation treated with insulin and without metformin
Timepoint [2] 0 0
24 weeks
Secondary outcome [3] 0 0
Reduction in FPG (overall and subpopulations)
Timepoint [3] 0 0
24 weeks
Secondary outcome [4] 0 0
Responder rates (overall and subpopulations)
Timepoint [4] 0 0
24 weeks
Secondary outcome [5] 0 0
Incidence of hypoglycemia and severe hypoglycemia (overall and subpopulations)
Timepoint [5] 0 0
24 weeks

Eligibility
Key inclusion criteria
* Confirmed diagnosis of T2DM
* On a stable dose of insulin as defined by the protocol
* On a stable does of metformin (if applicable) as defined by the protocol
* Age 18 to 80 years
* HbA1c of 7.5 to 11.0%
* Body Mass Index (BMI) 22 to 40 kg/m2
Minimum age
18 Years
Maximum age
80 Years
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
* Type 1 diabetes
* Short-acting or rapid-acting insulin
* Pregnancy or lactation
* Evidence of serious diabetic complications
* Evidence of serious cardiovascular complications
* Laboratory value abnormalities as defined by the protocol
* Other protocol-defined inclusion/exclusion criteria may apply

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
1/09/2010
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
1/10/2011
Sample size
Target
Accrual to date
Final
448
Recruitment in Australia
Recruitment state(s)
Recruitment hospital [1] 0 0
Novartis Investigative Site - Box Hill
Recruitment hospital [2] 0 0
Novartis Investigative Site - Heidelberg Heights
Recruitment hospital [3] 0 0
Novartis Investigative Site - Parkville
Recruitment hospital [4] 0 0
Novartis Investigative Site #1 - Wollongong
Recruitment hospital [5] 0 0
Novartis Investigative Site #2 - Wollongong
Recruitment postcode(s) [1] 0 0
- Box Hill
Recruitment postcode(s) [2] 0 0
- Heidelberg Heights
Recruitment postcode(s) [3] 0 0
- Parkville
Recruitment postcode(s) [4] 0 0
- Wollongong
Recruitment outside Australia
Country [1] 0 0
Belgium
State/province [1] 0 0
Bonheiden
Country [2] 0 0
Belgium
State/province [2] 0 0
Edegem
Country [3] 0 0
Belgium
State/province [3] 0 0
Genk
Country [4] 0 0
Belgium
State/province [4] 0 0
La Louviere
Country [5] 0 0
Belgium
State/province [5] 0 0
Ronse
Country [6] 0 0
Czech Republic
State/province [6] 0 0
Ostrava
Country [7] 0 0
Germany
State/province [7] 0 0
Asslar
Country [8] 0 0
Germany
State/province [8] 0 0
Bensheim
Country [9] 0 0
Germany
State/province [9] 0 0
Berlin
Country [10] 0 0
Germany
State/province [10] 0 0
Einbeck
Country [11] 0 0
Germany
State/province [11] 0 0
Hamburg
Country [12] 0 0
Germany
State/province [12] 0 0
Hannover
Country [13] 0 0
Germany
State/province [13] 0 0
Kassel
Country [14] 0 0
Germany
State/province [14] 0 0
Munchen
Country [15] 0 0
Germany
State/province [15] 0 0
Neubukow
Country [16] 0 0
Germany
State/province [16] 0 0
Saarlouis
Country [17] 0 0
Germany
State/province [17] 0 0
Tubingen
Country [18] 0 0
Guatemala
State/province [18] 0 0
Guatemala City
Country [19] 0 0
Hong Kong
State/province [19] 0 0
Hong Kong
Country [20] 0 0
Hungary
State/province [20] 0 0
Budapest
Country [21] 0 0
Hungary
State/province [21] 0 0
Dunaujvaros
Country [22] 0 0
Hungary
State/province [22] 0 0
Nyiregyhaza
Country [23] 0 0
Hungary
State/province [23] 0 0
Szeged
Country [24] 0 0
India
State/province [24] 0 0
Indore
Country [25] 0 0
India
State/province [25] 0 0
Jaipur
Country [26] 0 0
India
State/province [26] 0 0
Karnal
Country [27] 0 0
India
State/province [27] 0 0
Mumbai
Country [28] 0 0
India
State/province [28] 0 0
Mumbia
Country [29] 0 0
India
State/province [29] 0 0
Nagpur
Country [30] 0 0
India
State/province [30] 0 0
Nasik
Country [31] 0 0
India
State/province [31] 0 0
Trivandrum
Country [32] 0 0
Romania
State/province [32] 0 0
Alba-Iulia
Country [33] 0 0
Romania
State/province [33] 0 0
Bucharest
Country [34] 0 0
Romania
State/province [34] 0 0
Oradea
Country [35] 0 0
Romania
State/province [35] 0 0
Targu-Mures
Country [36] 0 0
Slovakia
State/province [36] 0 0
Banska Bystrica
Country [37] 0 0
Slovakia
State/province [37] 0 0
Bratislava
Country [38] 0 0
Slovakia
State/province [38] 0 0
Kosice
Country [39] 0 0
Slovakia
State/province [39] 0 0
Presov
Country [40] 0 0
Slovakia
State/province [40] 0 0
Sturovo
Country [41] 0 0
United Kingdom
State/province [41] 0 0
Carmarthen
Country [42] 0 0
United Kingdom
State/province [42] 0 0
Glasgow

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
Novartis
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Novartis Pharmaceuticals
Address 0 0
Novartis Pharmaceuticals
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries

No information has been provided regarding IPD availability


What supporting documents are/will be available?

No Supporting Document Provided



Results publications and other study-related documents

TypeCitations or Other Details
Journal Kozlovski P, Foley J, Shao Q, Lukashevich V, Kothn... [More Details]

Results not provided in https://clinicaltrials.gov/study/NCT01224366